Scroll | 28/01/2022 07:46 PM | Click to read full article
The Drugs Controller General of India on Friday gave approval to biotechnology company Bharat Biotech to conduct trials of its intranasal Covid-19 booster dose in India, reported ANI.
The subject expert committee of the drug regulator had three weeks ago given its recommendation that for phase 3 trials of the intranasal dose. The trials will be held in nine states, according to ANI. The Hyderabad-based manufacturer has proposed the booster dose for those who have already received Covishield and Covaxin vaccines, reported Mint.